Medaffcon

💬 Our abstract (End of Life Resource Use of Real-World NSCLC Patients in Finland) has been accepted to ISPOR Europe 2024! 🇪🇸 💡 In our poster we present results from our ongoing study on the end-of-life care and resource utilization among non-small cell lung cancer (NSCLC) patients in Finland. This study was conducted by researchers from HUS, The Wellbeing Services County of Kymenlaakso and Medaffcon.   🤝 Join us at the poster on November 19th from 10:30 a.m. to 1:30 p.m. to meet Riikka Mattila and Johanna Vikkula, and discuss lung cancer, Nordic health data, and exciting RWE opportunities in Finland.   Please come, meet and discuss with us at #ISPOREurope!   ➡️ Check here more: https://lnkd.in/d3zTDbu6  ➡️ Read more about #Medaffcon: https://lnkd.in/d69-SFXi Bettina Mannerström   #RWE #LungCancer #AI #Healthcare

Medaffcon is participating ISPOR Europe 2024 (ISPOR—The Professional Society for Health Economics and Outcomes Research), Barcelona, Spain Jarmo Hahl (Principal Consultant), Riikka Mattila (Scientific Advisor), Johanna Vikkula (Sr. Data Scientist) and Lisse-Lotte Hermansson (Country Director Sweden) will participate on Medaffcon’s behalf.  🙌 You can meet our experts at the Real-World Evidence Summit on Sunday (Nov 17th), or during the main event from Monday to Wednesday (Nov 18th-20th). We would be delighted to discuss Real-World Evidence related opportunities with you at ISPOR in #Barcelona. 🇪🇸 🫶 We hope to see many of you at the congress! 💯 ➡️ Please book a meeting with us to discuss further ➡️ info@medaffcon.fi #ISPOREurope #Pharmaceutical #RWE #RealWorldEvidence #Europe

👏 👏 👏 Over 3000 thousand followers - Thank you for everyone! 👏 👏 👏 ❤️ Have a great weekend for everyone! ❤️ #Medaffcon #Pharma #RWE #Nordic #MarketAccess #HEOR

📊 👩💻 🇸🇪 The Medaffcon team in #Sweden was strengthened at the beginning of October when Lisse-Lotte Hermansson started as the Director responsible for Swedish operations. Lisse-Lotte holds a Master of Science in Economics from the Helsinki School of Economics and is the first Master of Health Economics from the Karolinska Institutet Institute in Stockholm. Currently, she is working on a doctoral dissertation about the value of data. She has worked with health data for about 20 years. What tasks are on your desk this week? 💊 🇩🇰 🇸🇪 A new drug received marketing authorization on October 1 st , and its reimbursement in the Nordic countries is currently being handled. The first launch country is Denmark, and we are doing preliminary preparations related to reimbursement with the Danish authorities. The drug will, of course, also be introduced in Sweden. Additionally, I participated in a Nordic expert meeting. What brings you the most joy in your work? 📍 I get to interact with smart people, so I am constantly learning something new. What would you like to learn next? 🎩 I would like to develop self-discipline to complete my dissertation, which focuses on the value of data. The topic is closely related to my work. I am really passionate about data utilization. We need good data for all solutions, and you can only get that from the Nordic countries. Truly unique aspects need to be highlighted boldly. You must not overpromise, but you can’t be too modest either. What do you do in your leisure time? 🏌️♂️⛳️🇨🇭 Our youngest plays in Swiss Golf´s international competitions. I feel like I’m on a break when I get to join as a caddie. It challenges me physically, emotionally, and socially. It’s a good way to disconnect from work-related matters. #Medaffcon #TeamMedaffcon #EmployerBranding #Pharma #RWE

❤️ Welcome Lisse-Lotte Hermansson 🇸🇪 Lisse-Lotte Hermansson (Country Director Sweden) started at Medaffcon 1st of October 2024. Previously she was at a Swedish-German company as CSO Chief Scientific Officer, consulting European companies about Nordic health data opportunities and market access. She has a M.Sc (Econ.) from Helsingin School of Economics and a M.Sc (Health Econ) from Karolinska. Additionally a Ph.D student at the University of Turku in Health Economics. She has obtained a long experience from global pharma and medtech. She has lived over 20 years in Sweden. The current development gives new possibilities to utilise data. With AI we can produce synthetic data and build digital twins that can actually support drug development and support healthcare providers. Innovative solutions are only useful if they are adopted to daily practice. Old ways of working will vanish and RWD will be acknowledged as an excellent option or support for RCTs. As RWD is enabling more cost-effective evidence generation for new treatments. Treatments need to be more personalised so that the right drugs, diagnostics and devices are used for the right patients at the right time. ❤️ Welcome Lisse-Lotte to Medaffcon Team! 🇸🇪 ➡️ Please contact Lisse-Lotte ➡️ https://lnkd.in/day5iuAK (ENG) https://lnkd.in/d5wUdsvk (FI) #RWE #Sweden #realworldevidence #RWD #pharmaceutical #Nordic

📍 Tietolupa myönnetty 11.9.2024 #Medaffcon: A retrospective database analysis of IBD patients in Finland Findata – Sosiaali- ja terveysalan tietolupaviranomainen | Social and Health Data Permit Authority #IBD #patients #Finland #database #HealthResearch

❤️ Medaffcon staff meet on Fridays for a weekly meeting. During the meeting, they go over the week’s news and hear about the company’s most important updates. Once a month, a healthy breakfast is offered at the Espoo office. These joint meetings help maintain team spirit and social relationships in a way that everyday work rarely allows.   😊 Wishing everyone a pleasant weekend! 👋 ❤️ Medaffconin henkilöstö tapaa perjantaisin viikkokokouksessa. Tapaamisessa kerrataan viikon kuulumisia ja kuullaan, mitkä ovat kulloinkin yrityksen tärkeimmät uutiset. Kerran kuukaudessa tarjolla on terveellinen aamupala Espoon toimistossa. Yhteiset tapaamiset pitävät yllä tiimihenkeä ja sosiaalisia suhteita tavalla, johon arkisen työn keskellä on vähemmän mahdollisuuksia.   😊 Mukavaa viikonvaihdetta kaikille! 👋   #Medaffcon #Pharmaceutical #TeamMedaffcon #EmployerBranding #HappyFriday

❤️ Medaffcon is participating ISPOR Europe 2024 (ISPOR—The Professional Society for Health Economics and Outcomes Research), Barcelona, #Spain With just under two months to go, we're gearing up for an exciting event filled with discussions, insights, and networking. 🤝 This year Jarmo Hahl (Principal Consultant), Riikka Mattila (Scientific Advisor), Johanna Vikkula (Sr. Data Scientist) and Lisse-Lotte Hermansson (Country Director #Sweden) will participate on Medaffcon’s behalf. You can meet our experts at the Real-World Evidence Summit on Sunday (Nov 17th), or during the main event from Monday to Wednesday (Nov 18th-20th).  🙂↔️ We would be delighted to discuss Real-World Evidence related opportunities with you at ISPOR in Barcelona. We hope to see many of you at the congress! 💯 😊 💫 ➡️ Please book a meeting with us to discuss further ➡️ info@medaffcon.fi #ISPOREurope #Pharmaceutical #RWE #Research #Medaffcon

🌍 New #RWE Study: Prognosis for Multiple Myeloma has Improved, but Prevalence is Increasing The prognosis for patients with multiple myeloma (MM) has improved as treatments have advanced, but the disease remains incurable. The prevalence of the disease is increasing in Finland as the population gets older. This is evident from a recently published nationwide retrospective study based on real-world evidence (RWE). The study reported patient characteristics, incidence rates, survival outcomes, comorbidities, and healthcare resource utilization (HCRU) of all adult Multiple Myeloma (MM) patients diagnosed in Finland between 2000 and 2021. 🌍 The real-world evidence (RWE) study was published by Annals of Hematology in July 2024. The study was sponsored by the #pharmaceutical company Takeda and conducted by Medaffcon in collaboration with several leading experts. The Medical Writer for the study was Medaffcon’s Scientific Advisor, PhD Essi Havula. 🇫🇮 Finland’s Largest Real-World Evidence (RWE) Study on Multiple Myeloma  Multiple myeloma (MM) is an incurable blood cancer that develops from plasma cells in the bone marrow. MM accounts for approximately 10 percent of all hematological cancers and primarily affects elderly individuals.  In Finland, the current median age at diagnosis is 70 years, and the age-standardized incidence rate is 2.5–3 cases per 100,000 people. 📊 “This is the largest RWE study on #multiple #myeloma ever conducted in Finland. This is certainly the strength of this study,” says Medaffcon’s Scientific Advisor, PhD Essi Havula, who was the Medical Writer for the study.  The analysis included a total of 7,070 MM patients diagnosed over 21 years (2000-2021) and their 21,210 age-, gender-, and region-matched controls. Kai Kysenius Anna Anttalainen Iiro Toppila Mariann Lassenius ➡️ Read the whole article here ➡️ https://lnkd.in/dx5iAZJ9 ➡️ The whole study is here ➡️ https://lnkd.in/d2iv6raQ #realworldevidence #nordic

🇸🇪 Johan Rehnberg, a Scientific Advisor and RWE Epidemiologist, started at Medaffcon in mid-August as an expert on Swedish registries, data sources, and healthcare. Rehnberg earned his PhD in Public Health in 2019, after which he worked as a postdoctoral researcher on several projects at the Karolinska Institute’s Aging Research Center.    📊 What tasks are on your desk this week?  I am learning Medaffcon’s procedures and getting familiar with the details. I’ve had the opportunity to explore the ongoing projects Medaffcon has in Sweden. I am figuring out how and from which sources we can best obtain the necessary data.    😀 What brings you the most joy in your work?  I enjoy the research process in all its phases. I conducted research earlier in my academic career. For example, the planning process in Medaffcon’s projects is fascinating. It’s exciting to see what works and what challenges arise. I enjoy finding solutions.     📚 What would you like to learn next?  This ties into my previous answer. I have experience with data and registries from my academic career. Now, I’m delving into the details of how we can find the best data and utilize it at Medaffcon. Swedish data and registries are excellent and can be used for many different purposes.    ⛷️⛵️🛠️ How do you spend your leisure time?   I’ve been skiing my whole life. Last winter, my partner and I went skiing in Japan. It had been a long-time dream of mine. Last summer, we bought an old sailboat and learned how to sail. I’m also learning how to repair it. We live in a small house, which comes with plenty of repair projects. I enjoy these, as they provide a good balance to my work by allowing me to do something with my hands. #Medaffcon #Sweden #Nordic #TeamMedaffcon #Pharmaceutical #RWE